Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
An article in the Washington Examiner said that when it comes to health insurance, quality matters too. The article cited a study, “The Effects of Antihypertensive Step-Therapy Protocols on Pharmaceutical and Medical Utilization and Expenditures,” published by The American Journal for Managed Care® (AJMC ®) in 2009. The study found that the initial reductions step therapy causes in pharmaceutical costs are overwhelmed by more than $99 per patient in additional emergency room visits and in-patient hospital stays.
An article on Markets Insider Thursday cited a study published by AJMC®. The study, “A Health Plan's Investigation of Healthy Days and Chronic Conditions,” found that patients with six chronic conditions (coronary artery disease, chronic obstructive pulmonary disease, hypertension, diabetes, congestive heart failure, and depression) experienced a greater number of physically and mentally unhealthy days than the population average.
The National Pharmaceutical Council’s Daily Newsfeed e-mail on Thursday highlighted an article published by AJMC®. The article, “VBID Summit Explores How Congress Can Make High-Deductible Plans Work for Consumers,” reported on the healthcare idea, value-based insurance design (VBID). VBID seeks to remove financial barriers to high-value care. The concept of VBID was pioneered by co-editor-in-chief of AJMC® A. Mark Frederick, MD.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen